325P Net treatment benefit (NTB) from either endocrine therapy plus palbociclib (ET/P) or capecitabine (C) in GEICAM/2013-02PEARL, a phase III trial in hormone receptor-positive, HER2-negative metastatic breast cancer | Publicación